此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Pilot Study for the Evaluation of the Safety and Performance of a Combined OCT System (Hydra01)

2020年3月31日 更新者:University Hospital, Basel, Switzerland

A Prospective,Open Label,Non-randomized,Single-centre,Exploratory,Stratified Pilot Study for the Evaluation of the Safety and Performance of a Combined Coaxial Optical Coherence Tomography (OCT) System,to Image Diseases of the Posterior and Anterior Segment of the Eye

The novel Coaxial Optical Coherence Tomography (OCT) System is designed to visualize both structures of the retina and choroid.

The purpose of this research is the safety and evaluation of a combined coaxial optical coherence tomography (OCT) system, to image diseases of the posterior and anterior segment of the eye.

研究概览

详细说明

Background and Rationale:

Many posterior segment ocular diseases involve the retinal and choroidal vasculature. A new technology to noninvasively and simultaneously visualize vascular pathology is of utmost importance to reduce patient exposure to different diagnosis methods like e.g. fluorescence angiography. The novel Coaxial Optical Coherence Tomography (OCT) System is designed to visualize both structures of the retina and choroid.

Furthermore, it may be used to image other structures of the eye.

Objective(s):

The purpose of this research is the safety and evaluation of a combined coaxial optical coherence tomography (OCT) system, to image diseases of the posterior and anterior segment of the eye. This device may be useful for the early diagnosis and monitoring of a variety of diseases involving the eye, such as Glaucoma, Diabetic Retinopathy or Age-Related Macular Degeneration. Measurements are compared to normal controls.

Measurements and procedures:

After screening, all participants will undergo a scanning procedure on the same day.

Only one eye of each participant will be scanned with the investigational device. For patients, the eye showing the disease will be chosen, for healthy volunteers, the left or right eye will be scanned according to a randomisation list.

The image quality is rated by the investigator and an independent assessor on a VAS (visual analogue scale). A subgroup of each stratum will have a comparative measurement of the choroid thickness against a SS-OCT (swept-source-OCT) device (Topcon) and a retina thickness against the Spectralis data. The subgroup will consist of half planned sample size. The measurement is taken from one eye, ie. every second participant per stratum will be attributed to the thickness measurement subgroup. The endpoint is a true/false criterion on whether the measurement of the retina and choroid thickness was successful. The thickness is measured in μm. The measurement is considered a "success" if the value is no more than +/- 10% off the reference measurement.

研究类型

介入性

注册 (实际的)

30

阶段

  • 不适用

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Subjects with healthy eye, or has been diagnosed already with eye disease
  • Patients > 18 years of age
  • Informed Consent as documented by date and signature

Exclusion Criteria:

  • Clinically significant concomitant disease that impair measurement
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, late stage Alzheimer disease, etc. of the participant,
  • Subjects using implanted electronic medical devices (e.g. cochlear implant, pacemaker, defibrillator, infusion pump).
  • Participation in another study with investigational drug within the 30 days preceding and during the present study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
其他:Healthy subjects
One eye of each participant will be scanned with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel
其他:Diseased groups
lf one eye is affected, this will be chosen. lf both eyes are be affected, the eye with the severest symptoms will be chosen. Scanning with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel
其他:Diseased subgroups

Every second subject will be allocated to the subgroup.

  1. Scanning with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
  2. Thickness measurement with reference medical device.
The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Visual acuity (VA) after investigation
大体时间:Within 1 hour after investigation
Safety of the imaging investigation expressed as visual acuity before (baseline) and after imaging, and tolerability assessment questionnaire.
Within 1 hour after investigation

次要结果测量

结果测量
措施说明
大体时间
Scan quality
大体时间:After completion of all measurement, an average of 2 years.
Comparing scan quality of investigational device to scan quality of a reference device, expressed as thickness of the retina and the thickness of the choroid
After completion of all measurement, an average of 2 years.
Procedural success
大体时间:After completion of all measurement, an average of 2 years.
Procedural success that is defined as: Image Quality of anterior and posterior eye structures
After completion of all measurement, an average of 2 years.
Procedural safety and comfort assessed by questionnaire
大体时间:Within 1 hour after investigation
Procedural comfort in the opinion of the patients assessed with a questionnaire
Within 1 hour after investigation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Hendrik PN Scholl, MD、University Hospital Basel, Dept. of Ophthalmology
  • 首席研究员:Pascal Hasler, MD、University Hospital Basel, Dept. of Ophthalmology

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2016年12月1日

初级完成 (实际的)

2017年3月1日

研究完成 (实际的)

2019年12月1日

研究注册日期

首次提交

2017年11月17日

首先提交符合 QC 标准的

2018年1月25日

首次发布 (实际的)

2018年2月5日

研究记录更新

最后更新发布 (实际的)

2020年4月1日

上次提交的符合 QC 标准的更新

2020年3月31日

最后验证

2020年3月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • 085-HAP-2017-001

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅